8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 10, 2026·SEC
Protara Therapeutics, Inc.(TARA)Earnings, Financials & Key Ratios
TARA•NASDAQ
$4.04
Price updated Jul 7, 2026
AboutProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$64M-31.5%
- Net Income-$57M-28.8%
- EPS (Diluted)-1.34+38.2%
- ROE-31.6%+16.6%
TARA Price & Volume
Protara Therapeutics, Inc. (TARA) stock price & volume — 10-year historical chart
Loading chart...
Protara Therapeutics Faces Critical Liquidity Runway Contraction
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- Protara Therapeutics remains a high-risk, pre-revenue biotechnology entity characterized by an aggressive R&D-led burn profile that has rapidly depleted its cash reserves.
- While the company maintains a clean balance sheet with a negligible debt-to-equity ratio of 0.02, the absence of commercial revenue necessitates ongoing reliance on dilutive equity financing to sustain clinical operations.
- Investors should monitor the company's ability to extend its $14.7 million cash runway, as the current $19.6 million quarterly operating loss trajectory poses a significant threat to long-term solvency without immediate capital infusion.
Verdict Logic
the company's cash position has plummeted to $14.7 million as of 2026Q1, which is insufficient to cover the current quarterly operating loss of $19.6 million without immediate external financing.
TARA Growth Metrics
Protara Therapeutics, Inc. (TARA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-39.4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.12%
Return on Capital
10 Years-57.9%
5 Years-39.63%
3 Years-41.25%
Last Year-34.98%
TARA Recent Earnings
Protara Therapeutics, Inc. (TARA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.31+13.9%
$0.36
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.37-15.6%
$0.32
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.31+20.5%
$0.39
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.35+18.6%
$0.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.31vs $0.36+13.9% | — |
| Q2 2026 | Mar 10, 2026 | $0.37vs $0.32-15.6% | — |
| Q4 2025 | Nov 10, 2025 | $0.31vs $0.39+20.5% | — |
| Q3 2025 | Aug 11, 2025 | $0.35vs $0.43+18.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Protara Therapeutics, Inc. (TARA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.04 | $155.9M | -3.01 | — | — | -31.6% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — |
Compare TARA vs Peers
Protara Therapeutics, Inc. (TARA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TARA SEC Filings & Documents
Protara Therapeutics, Inc. (TARA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TARA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TARA Frequently Asked Questions
Protara Therapeutics, Inc. (TARA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TARA profitable?
Protara Therapeutics, Inc. (TARA) reported a net loss of $63.3M for fiscal year 2025.
Dividend & Returns
What is TARA's return on equity?
Protara Therapeutics, Inc. (TARA) has a return on equity (ROE) of -31.6%. Negative ROE indicates the company is unprofitable.
What is Protara Therapeutics, Inc.'s free cash flow?
Protara Therapeutics, Inc. (TARA) had negative free cash flow of $63.0M in fiscal year 2025, likely due to heavy capital investments.